Synthesis and cytotoxicity testing of novel 2-(3-substituted-6-chloro-1,1- dioxo-1,4,2-benzodithiazin-7-yl)-3-phenyl-4(3H)-quinazolinones

Archiv der Pharmazie

Volumn 341, Issue 8, 2008, Pages 485-490

  Pomarnacka, Elzbieta ^a   Maruszak, Magdalena ^a,b   Langowska, Karolina ^a,b   Reszka, Przemyslaw ^b   Bednarski, Patrick J ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

2 Substituted 3 phenyl 4(3H) quinazolinones; Cytotoxic activity; Synthesis

Indexed keywords

2 (3 ALLYLAMINO 6 CHLORO 1,1 DIOXO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 1,1 DIOXO 3 4 TOLYLAMINO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 1,1 DIOXO 3 PHENETHYLAMINO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 1,1 DIOXO 3 PIPERIDIN 1 YL 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 1,1 DIOXO 3 PROP 2 YNYLAMINO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 1,1 DIOXO 3 PYRROLIDIN 1 YL 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 3 BENZYLAMINO 1,1 DIOXO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO 3 ISOPROPYLAMINO 1,1 DIOXO 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 (6 CHLORO1,1 DIOXO 3 MORPHOLIN 4 YL 1,4,2 BENZODITHIAZIN 7 YL) 3 PHENYL 4(3H)QUINAZOLINONE; 2 [6 CHLORO 1,1 DIOXO 3 (2 PYRIDIN 2 YLETHYLAMINO) 1,4,2 BENZODITHIAZIN 7 YL] 3 PHENYL 4(3H)QUINAZOLINONE; 2 [6 CHLORO 1,1 DIOXO 3 [(PYRIDIN 3 YLMETHYL)AMINO] 1,4,2 BENZODITHIAZIN 7 YL] 3 PHENYL 4(3H)QUINAZOLINONE; 2 [6 CHLORO 3 (3 HYDROXYPROPYLAMINO) 1,1 DIOXO 1,4,2 BENZODITHIAZIN 7 YL] 3 PHENYL 4(3H)QUINAZOLINONE; 2 [6 CHLORO 3 (4 PHENYLPIPERAZIN 1 YL) 1,1 DIOXO 1,4,2 BENZODITHIAZIN 7 YL] 3 PHENYL 4(3H)QUINAZOLINONE; CISPLATIN; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; THIAZINE DERIVATIVE;

ARTICLE; BIOASSAY; CANCER GROWTH; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; CHEMISTRY; DRUG SCREENING; IC 50; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; QUINAZOLINONES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES;

EID: 53149122527     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700258     Document Type: Article

References (26)

1. A. K. Tiwari, A. K. Mishra, A. Bajpai, P. Mishra, et al., Bioorg. Med. Chem. Lett. 2006, 16, 4581-4585.
2. A. R. Khosropour, I. Mohammadpoor-Baltork, H. Ghorbankhani, Tetrahedron Lett. 2006, 47, 3561-3564.
3. V. Alagarsamy, U. S. Pathak, Bioorg. Med. Chem. 2007, 15, 3457-3462.
4. G. Grover, S. G. Kini, Eur. J. Med. Chem. 2006, 41, 256-262.
5. A. Kumar, S. Sharma, K. Bajaj, H. Panwar, et al., Bioorg. Med. Chem. 2003, 11, 5293-5299.
6. Y. Xia, Z.-Y. Yang, M.-J. Hour, S.-C. Kyo, et al., Bioorg. Med. Chem. Lett. 2001, 11, 1193-1196.
7. S. Cao, Y. Feng, Y. Jiang, S. Liu, et al., Bioorg. Med. Chem. Lett. 2005, 15, 1915-1917.
8. T. M. Abdel-Rahman, J. Heterocycl Chem. 2006, 43, 527-534.
9. J. B. Jiang, D. P. Hesson, B. A. Dusak, D. L. Dexter, et al., J. Med. Chem. 1990, 33, 1721-1728.
10. D. Raffa, B. Daidone, S. Maggio, F. Cascioferro, et al., Farmaco 2004, 59, 215-222.
11. D. Raffa, B. Daidone, S. Maggio, F. Cascioferro, et al., Farmaco 2004, 59, 451-455.
12. E. Pomarnacka, Z. Brzozowski, Acta Pol. Pharm. Drug Res. 1997, 54, 215-221.
13. E. Pomarnacka, A. Kornicka, Farmaco 2001, 56, 571-577.
14. E. Pomarnacka, I. Kozlarska-Kedra, Farmaco 2003, 58, 423-429.
15. L. C. Kuo, H. Assefa, Z. Brzozowski, J. Slawinski, et al., J. Med. Chem. 2004, 47, 385-399.
16. E. Pomarnacka, M. Gdaniec, Bioorg. Med. Chem. 2003, 11, 1259-1267.
17. Z. Brzozowski, F. Saczewski, M. Gdaniec, Eur. J. Med. Chem. 2003, 38, 991-999.
18. E. Pomarnacka, A. Kornicka, F. Saczewski, Heterocycles 2001, 55, 753-760.
19. Z. Brzozowski, F. Saczewski, J. Med. Chem. 2002, 45, 430-437.
20. Z. Brzozowski, F. Saczewski, J. Slawinski, P. J. Bednarski, et al., Bioorg. Med. Chem. 2007, 15, 2560-2572.
21. E. Pomarnacka, P. J. Bednarski, P. Reszka, E. Dziemidowicz-Borys, et al., Eur. J. Med. Chem. 2006, 41, 633-639.
22. Z. Brzozowski, J. Slawinski, Eur. J. Med. Chem. 2006, 41, 1180-1189.
23. Z. Brzozowski, J. Slawinski, Acta Pol. Pharm. 1984, 41, 5-13.
24. Z. Brzozowski, F. Gajewski, J. Slawinski, E. Pomarnacka, Acta Pol. Pharm. Drug Res. 1993, 50, 199-203.
25. K. Bracht, Boubakari, R. Grünert, P. J. Bednarski, Anticancer Drugs 2006, 17, 41-51.
26. K. Rinke, R. Grünert, P. J. Bednarski, Pharmazie 2001, 56, 763-769.